Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA Net Income 2011-2026 | BPTS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - -31.2 M -17.1 M -17.8 M -14 M -11.4 M -7.95 M -3.29 M -709 K -522 K - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
-522 K -31.2 M -11.6 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-514 M - 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
-14.8 M - -10.17 % $ 12.2 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-221 M $ 1.37 -8.67 % $ 350 M britainBritain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-208 M - - $ 1.01 B usaUSA
Adagene Adagene
ADAG
-33.4 M $ 1.65 6.11 % $ 92.9 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-12.8 M $ 3.43 -2.69 % $ 8.25 B australiaAustralia
Biogen Biogen
BIIB
1.63 B $ 177.93 -4.15 % $ 25.9 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
-1.63 M $ 65.89 -0.06 % $ 8.81 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
603 M - - $ 40.3 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-252 M - - $ 3.67 B usaUSA
AVROBIO AVROBIO
AVRO
12.2 M - 1083.1 % $ 745 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.09 M - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-5.46 M - -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
115 M $ 94.4 0.82 % $ 96.9 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-645 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
-25 M - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
-98 M - -7.31 % $ 87 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
72.9 M - - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-384 M $ 214.55 2.77 % $ 5 B danmarkDanmark
Codiak BioSciences Codiak BioSciences
CDAK
-37.2 M - -55.98 % $ 2.15 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-83.7 M - 1052.0 % $ 415 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
-8.95 B $ 55.84 0.13 % $ 113 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
-433 M - - $ 7.29 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-9.57 M - 4.01 % $ 150 M canadaCanada
Caladrius Biosciences Caladrius Biosciences
CLBS
-20 M - -16.75 % $ 25.8 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-27.1 M $ 2.86 - $ 908 M israelIsrael
Clearside Biomedical Clearside Biomedical
CLSD
-32.5 M - - $ 25.3 M usaUSA
Chimerix Chimerix
CMRX
-82.1 M - - $ 756 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-114 M - -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
10.3 B $ 106.88 4.6 % $ 27.2 B germanyGermany
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-7.88 M $ 4.18 -1.65 % $ 9.1 B israelIsrael
AIkido Pharma AIkido Pharma
AIKI
-14.7 M - 1.93 % $ 17.4 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
-85.5 M $ 11.09 1.0 % $ 730 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-34 M - -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
-26.2 M - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-57.8 M - - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
-58.8 M - 4.14 % $ 49.1 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-38 M - - $ 7.46 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
-238 M $ 1.69 2.12 % $ 159 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-8.63 M - -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
160 M $ 28.99 -1.39 % $ 1.4 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-158 M $ 25.71 0.16 % $ 1.66 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
-93 M - - $ 1.2 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-125 M $ 4.24 -0.47 % $ 116 M franceFrance
Acorda Therapeutics Acorda Therapeutics
ACOR
-253 M - -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-126 M - - $ 10.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-5.69 M - -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
172 M $ 9.57 -0.78 % $ 1.55 B britainBritain